Grant: Discovery Grants Program - Individual
University of Alberta
$30,000.00
Interactions between parasite surface antigens and host responses to Plasmodium falciparum and P. vivax.
EF 2015-16
Résumé
The parasitePlasmodium (P.) has co-evolved exquisitely with its human host over thousands of years. Six species infect humans and over two hundred other species infect animals including reptiles, birds and mammals. The effects of Plasmodium on these hosts vary from benign to lethal infections, depending on the virulence of the parasite and the ability of the host to respond to infection. In humans, P. falciparum causes significant pathogenesis, while other species such as P. vivax appear less virulent with lower parasitemia and fewer pathogenetic effects on the host.
<span style=""line-height: 1.5em;"">The expression of surface proteins on the infected red blood cell highlights a key immune evasion strategy evolved by P. falciparum. These proteins mediate cellular adhesion through interaction with specific ligands on human epithelial cells. The surface proteins are encoded by the `var' gene family, which consists of approximately 60 genes in the P. falciparum genome. Expression of var genes is controlled by a genetic mechanism of allelic exclusion whereby parasites switch expression to a different var gene with each generation and presents a different surface antigen that is new to the immune system.
Immunity is gradually acquired upon exposure to multiple surface variants. An important exception is in pregnancy where antibodies fail to recognize a particular VAR protein, PfVAR2CSA, which mediates cytoadherence in the placenta. Based on studies in Africa, the current view is that the expression of var2csa is silenced except in placental parasites, and antibodies are only measured in pregnant women after exposure to placental infection. However, we challenged this view with some startling observations from Colombia: 1) We measured high levels of antibodies to PfVAR2CSA in men and children, and 2) Men, women and children exposed only to P. vivax had antibodies to this P. falciparum protein.
These findings present a biological puzzle that we want to unravel in the proposed research program. An important clue may be that in Africa, P. falciparum is the predominant species whereas in Colombia, both P. falciparum and P. vivax co-evolved. We propose that this geographical overlap led to evolutionary changes in parasites that altered their mechanisms of immune evasion. Building on my expertise in basic cell biology and genetics, my research program will investigate the genetic control of var gene expression, characterize the DNA sequences and perform phylogenetic analyses of Colombian isolates, identify sequences that define the cross-reactivity of antibodies between P. falciparum and P. vivax and map these epitopes, and test for adhesion of these antibodies to specific ligands in parasite cultures and in vivo. Collectively, my research proposal will focus on probing the genetic and immunological interactions between two major species of Plasmodium.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2015-04790
Name nom
Yanow, Stephanie
Department département
Medical Microbiology and Immunology - Medical Microbiology and Immunology
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
30000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5204
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Immunology
Research subject fr
Immunologie
Partie
1
Nb partie
1
Application title
Interactions between parasite surface antigens and host responses to Plasmodium falciparum and P. vivax.
Keyword
NSERC
Application summary
<p>The parasite<em>Plasmodium</em> (<em>P.</em>) has co-evolved exquisitely with its human host over thousands of years. Six species infect humans and over two hundred other species infect animals including reptiles, birds and mammals. The effects of <em>Plasmodium</em> on these hosts vary from benign to lethal infections, depending on the virulence of the parasite and the ability of the host to respond to infection. In humans, <em>P. falciparum</em> causes significant pathogenesis, while other species such as <em>P. vivax</em> appear less virulent with lower parasitemia and fewer pathogenetic effects on the host. </p>
<p><span style=""line-height: 1.5em;"">The expression of surface proteins on the infected red blood cell highlights a key immune evasion strategy evolved by </span><em>P. falciparum</em>. These proteins mediate cellular adhesion through interaction with specific ligands on human epithelial cells. The surface proteins are encoded by the `<em>var</em>' gene family, which consists of approximately 60 genes in the <em>P. falciparum</em> genome. Expression of <em>var</em> genes is controlled by a genetic mechanism of allelic exclusion whereby parasites switch expression to a different <em>var</em> gene with each generation and presents a different surface antigen that is new to the immune system. <br />
<br />
Immunity is gradually acquired upon exposure to multiple surface variants. An important exception is in pregnancy where antibodies fail to recognize a particular VAR protein, PfVAR2CSA, which mediates cytoadherence in the placenta. Based on studies in Africa, the current view is that the expression of <em>var2csa</em> is silenced except in placental parasites, and antibodies are only measured in pregnant women after exposure to placental infection. However, we challenged this view with some startling observations from Colombia: 1) We measured high levels of antibodies to PfVAR2CSA in men and children, and 2) Men, women and children exposed only to <em>P. vivax</em> had antibodies to this <em>P. falciparum</em> protein. <br />
<br />
These findings present a biological puzzle that we want to unravel in the proposed research program. An important clue may be that in Africa, <em>P. falciparum</em> is the predominant species whereas in Colombia, both <em>P. falciparum</em> and <em>P. vivax</em> co-evolved. We propose that this geographical overlap led to evolutionary changes in parasites that altered their mechanisms of immune evasion. Building on my expertise in basic cell biology and genetics, my research program will investigate the genetic control of <em>var </em>gene expression, characterize the DNA sequences and perform phylogenetic analyses of Colombian isolates, identify sequences that define the cross-reactivity of antibodies between <em>P. falciparum</em> and <em>P. vivax</em> and map these epitopes, and test for adhesion of these antibodies to specific ligands in parasite cultures and <em>in vivo</em>. Collectively, my research proposal will focus on probing the genetic and immunological interactions between two major species of <em>Plasmodium</em>.<br />
<br />
<br />
</p>